191 related articles for article (PubMed ID: 38216550)
21. Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre.
Lau DK; Fong C; Arouri F; Cortez L; Katifi H; Gonzalez-Exposito R; Razzaq MB; Li S; Macklin-Doherty A; Hernandez MA; Hubank M; Fribbens C; Watkins D; Rao S; Chau I; Cunningham D; Starling N
BMC Cancer; 2023 Apr; 23(1):380. PubMed ID: 37101114
[TBL] [Abstract][Full Text] [Related]
22. Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase.
Falvella FS; Caporale M; Cheli S; Martinetti A; Berenato R; Maggi C; Niger M; Ricchini F; Bossi I; Di Bartolomeo M; Sottotetti E; Bernardi FF; de Braud F; Clementi E; Pietrantonio F
Int J Mol Sci; 2015 Apr; 16(4):8884-95. PubMed ID: 25906475
[TBL] [Abstract][Full Text] [Related]
23. Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies.
Galarza AF; Linden R; Antunes MV; Hahn RZ; Raymundo S; da Silva AC; Staggemeier R; Spilki FR; Schwartsmann G
Clin Biochem; 2016 Nov; 49(16-17):1221-1226. PubMed ID: 27399164
[TBL] [Abstract][Full Text] [Related]
24. Severe fluoropyrimidine-related toxicity: clinical implications of DPYD analysis and UH2/U ratio evaluation.
Giorgio E; Caroti C; Mattioli F; Uliana V; Parodi MI; D'Amico M; Fucile C; Marini V; Forzano F; Cassola G; Martelli A; Faravelli F; Di Maria E
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1355-61. PubMed ID: 21833589
[TBL] [Abstract][Full Text] [Related]
25. Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5-fluorouracil toxicity.
Hamzic S; Schärer D; Offer SM; Meulendijks D; Nakas C; Diasio RB; Fontana S; Wehrli M; Schürch S; Amstutz U; Largiadèr CR
Br J Clin Pharmacol; 2021 Aug; 87(8):3234-3243. PubMed ID: 33491253
[TBL] [Abstract][Full Text] [Related]
26. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.
Amstutz U; Henricks LM; Offer SM; Barbarino J; Schellens JHM; Swen JJ; Klein TE; McLeod HL; Caudle KE; Diasio RB; Schwab M
Clin Pharmacol Ther; 2018 Feb; 103(2):210-216. PubMed ID: 29152729
[TBL] [Abstract][Full Text] [Related]
27. Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.
Lunenburg CATC; Henricks LM; Dreussi E; Peters FP; Fiocco M; Meulendijks D; Toffoli G; Guchelaar HJ; Swen JJ; Cecchin E; Schellens JHM; Gelderblom H
Eur J Cancer; 2018 Nov; 104():210-218. PubMed ID: 30361102
[TBL] [Abstract][Full Text] [Related]
28. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
[TBL] [Abstract][Full Text] [Related]
29. The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients.
Loganayagam A; Arenas-Hernandez M; Fairbanks L; Ross P; Sanderson JD; Marinaki AM
Cancer Chemother Pharmacol; 2010 Jan; 65(2):403-6. PubMed ID: 19795123
[TBL] [Abstract][Full Text] [Related]
30. Pharmacogenetics and Metabolism from Science to Implementation in Clinical Practice: The Example of Dihydropyrimidine Dehydrogenase.
Del Re M; Restante G; Di Paolo A; Crucitta S; Rofi E; Danesi R
Curr Pharm Des; 2017; 23(14):2028-2034. PubMed ID: 28128059
[TBL] [Abstract][Full Text] [Related]
31. Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.
Thomas F; Hennebelle I; Delmas C; Lochon I; Dhelens C; Garnier Tixidre C; Bonadona A; Penel N; Goncalves A; Delord JP; Toulas C; Chatelut E
Clin Pharmacol Ther; 2016 Feb; 99(2):235-42. PubMed ID: 26265035
[TBL] [Abstract][Full Text] [Related]
32. Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction.
Gentile G; Botticelli A; Lionetto L; Mazzuca F; Simmaco M; Marchetti P; Borro M
Pharmacogenomics J; 2016 Aug; 16(4):320-5. PubMed ID: 26216193
[TBL] [Abstract][Full Text] [Related]
33.
Ragia G; Biziota E; Koukaki T; Amarantidis K; Manolopoulos VG
Pharmacogenomics; 2024 Jan; 25(2):59-67. PubMed ID: 38353109
[TBL] [Abstract][Full Text] [Related]
34. Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a
Ockeloen CW; Raaijmakers A; Hijmans-van der Vegt M; Bierau J; de Vos-Geelen J; Willemsen AE; van den Bosch BJ; Coenen MJ
J Oncol Pharm Pract; 2023 Jan; 29(1):5-13. PubMed ID: 34797200
[TBL] [Abstract][Full Text] [Related]
35. Patients carrying DPYD variant alleles have increased risk of severe toxicity and related treatment modifications during fluoropyrimidine chemotherapy.
Shakeel F; Fang F; Kwon JW; Koo K; Pasternak AL; Henry NL; Sahai V; Kidwell KM; Hertz DL
Pharmacogenomics; 2021 Feb; 22(3):145-155. PubMed ID: 33410339
[No Abstract] [Full Text] [Related]
36. Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene.
Kuilenburg ABPV; Meijer J; Tanck MWT; Dobritzsch D; Zoetekouw L; Dekkers LL; Roelofsen J; Meinsma R; Wymenga M; Kulik W; Büchel B; Hennekam RCM; Largiadèr CR
Biochim Biophys Acta; 2016 Apr; 1862(4):754-762. PubMed ID: 26804652
[TBL] [Abstract][Full Text] [Related]
37. Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy.
Amstutz U; Offer SM; Sistonen J; Joerger M; Diasio RB; Largiadèr CR
Clin Cancer Res; 2015 May; 21(9):2038-44. PubMed ID: 25655103
[TBL] [Abstract][Full Text] [Related]
38. DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview.
Paulsen NH; Vojdeman F; Andersen SE; Bergmann TK; Ewertz M; Plomgaard P; Hansen MR; Esbech PS; Pfeiffer P; Qvortrup C; Damkier P
Basic Clin Pharmacol Toxicol; 2022 Nov; 131(5):325-346. PubMed ID: 35997509
[TBL] [Abstract][Full Text] [Related]
39. Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine-induced toxicity in an Asian population.
Kanai M; Kawaguchi T; Kotaka M; Manaka D; Hasegawa J; Takagane A; Munemoto Y; Kato T; Eto T; Touyama T; Matsui T; Shinozaki K; Matsumoto S; Mizushima T; Mori M; Sakamoto J; Ohtsu A; Yoshino T; Saji S; Matsuda F
Cancer Med; 2023 Apr; 12(7):7808-7814. PubMed ID: 36524458
[TBL] [Abstract][Full Text] [Related]
40. [New recommendation on pharmacogenetic screening prior to 5-fluorouracil based cancer treatment - Swedish experience indicates less adverse effects and healthcare cost savings].
Schultz A; Kohnke H; Wadelius M; Nygren P
Lakartidningen; 2021 Aug; 118():. PubMed ID: 34498246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]